Glucotrack Inc (GCTK) Institutional Ownership Tracker (Q2 2026)

AI summary pending

Glucotrack (ticker: GCTK) executed a 1-for-15 reverse stock split effective August 28, 2026, following shareholder approval at its annual meeting on August 18. The move reduced shares outstanding from roughly 11.97 million to approximately 798,144, with every 15 shares combining into one and any fractional shares rounded up. Outstanding stock options and warrants were proportionally adjusted, the ticker stays GCTK, and split-adjusted trading begins at market open on August 31.

No AI summary for this filing type

AI summary pending

Glucotrack (GCTK) entered Amendment No. 1 to its common stock purchase agreement with White Lion Capital on August 7, 2026. Under the amendment, the company will issue 2,505,513 commitment shares within one business day after the resale registration statement goes effective, a number based on the $1 million commitment fee divided by the minimum price. It also adds a true-up provision: if the commitment fee price is below the minimum price, Glucotrack owes a cash true-up amount within 120 days after the measurement date; if it's at or above that minimum, no payment is due.

AI summary pending

Glucotrack (GCTK) issued a joint press release with Lokahi Therapeutics on July 29, 2026, and furnished it as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The excerpt only confirms the press release was issued — it doesn't include what the release actually said.

AI summary pending

Glucotrack (ticker GCTK) entered an exchange agreement on July 22, 2026, with an existing investor to carve out a $900,000 promissory note from a larger $3.6 million note (already reduced by prior exchanges). The investor can convert this new note into common stock at a price equal to the lower of the Nasdaq closing price on the exchange date or the average of the prior five days, with no cash payment required.

Glucotrack, Inc. entered into a merger agreement on July 14, 2026, with an acquiring entity. Under the terms, Glucotrack will merge into a subsidiary of the acquiror, and shareholders will receive shares of the acquiror's common and preferred stock. The company also plans a private placement offering of up to $30 million to fund the transaction.